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Primary liver carcinoma is the most important malignant disease. The nodular metastatic foci of liver carcinoma are
usually found in the lung, adrenal gland or abdomen after resection or transplantation. Pulmonary lymphangitic
carcinomatosis (PLC) accounts for approximately 6% to 8% of metastatic cancer in the lung. The occurrence of PLC
is extremely rare in liver carcinoma. Herein we report the case of a patient with PLC after liver transplantation due
to liver carcinoma. PLC was confirmed by clinical manifestations, imaging studies and cytologic examination of
exfoliated cells in the pleural effusion.
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Primary liver carcinoma is a malignancy originating from
hepatocytes and/or intrahepatic biliary epithelial cells. In
China, there are more than 90 million carriers of the hepa-
titis B virus (HBV), accounting for 40% to 45% of HBV
carriers worldwide. The high prevalence of HBV in China
is the underlying reason why liver carcinoma is the malig-
nancy with the highest morbidity and mortality rates in
China. Currently, resection and liver transplantation are
major strategies for the treatment of liver carcinoma. For
patients with hepatic cirrhosis, liver transplantation can
cure both the cancer and liver cirrhosis. However, liver
carcinoma may recur or metastasize after resection or
liver transplantation, mainly via the hematogenous route.
Although lymphatic metastasis can occur, metastasis is
usually found in the hepatic hilus, upper abdomen and
retroperitoneal lymph nodes [1]. Pulmonary lymphangitic
carcinomatosis (PLC) is a special manifestation of meta-
static cancer in the lymphatic vessels of the lung that is
characterized by diffuse or focal growth. Most PLC
cases originate from adenocarcinomas. PLC is rare in
liver carcinoma patients. To the best of our knowledge,
no studies reported to date have described PLC after
liver transplantation.* Correspondence: zyzss@zju.edu.cn
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A 45-year-old man was admitted to our hospital with a
complaint of repeated episodes of abdominal distension.
He was diagnosed with HBV-induced hepatic cirrhosis
and liver carcinoma (T3N0M0). He underwent liver trans-
plantation without any metastasis before the operation.
Pathological analysis identified a tumor (12 cm × 8 cm×
10 cm) in the right lobe of the liver, within which the can-
cer cells were arranged in nests and pleomorphism was
seen. These findings, together with the results of immuno-
histochemistry, demonstrated features of mixed liver car-
cinoma: α-fetoprotein (+), hepatocytes (+), CD34 (+),
CD19 (+), CD10 (focal, +), synaptophysin (−), chromogra-
nin A (−) and cytokeratin (pan, +) (Figure 1). The function
of the graft liver was favorable. FK506 was used alone for
antirejection therapy.
Two months later the patient developed a dry cough of
unknown etiology, and his condition deteriorated 1 week
later. Expectoration was occasionally present, accompan-
ied by chest tightness, shortness of breath and hypoxemia
(75 mmHg partial pressure of oxygen). Fever and chills
were absent, and the patient’s white blood cell count, neu-
trophil count and inflammatory factors were normal. His
sputum culture was negative. Lung computed tomography
(CT) suggested infectious lesions in the lung, which were
characterized by interstitial changes. Right-sided pleural
effusion and segmental atelectasis in the lower lobe of the
right lung were noted. Several enlarged lymph nodes were
identified in the mediastinum (Figure 2A). Thoracentesisl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Immunohistochemical staining of mixed liver carcinoma
tissue specimens. (A) Cancer cells were arranged in nests and
showed atypia. The interstitium was rich in sinusoids, and invasive
growth was noted. (B) Image showing cytokeratin 19 (CK19) (+). (C)
Image showing CK7 (+). All three images are stained with hematoxylin
and eosin and were scanned at 100× original magnification.
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of light yellow fluid was collected. The patient’s chest
tightness and shortness of breath improved significantly.
Posttransplantation interstitial pneumonia was considered
at first. FK506 was discontinued, and methylprednisolone
(40 mg every 12 hours), caspofungin, sulfamethoxazole
(SMZ) and aminophylline were administered.
Five days later a lung CT scan showed reexpansion of the
right lung and diffuse exudate in the interstitium. Multiple
nodules were found in both lungs (Figure 2B). Pulmonary
function tests showed severe obstructive ventilatory dys-
function and moderate reduction in carbon monoxide
diffusion capacity. Examination of exfoliated cells in the
pleural effusion showed cancer cells (Figure 3). Positron
emission tomography (PET)-CT indicated multiple nodules
and patchy or cloudy shadows with high density in both
lungs (maximal standardized uptake value (SUV) approxi-
mately 6.27). Several enlarged lymph nodes were found in
the mediastinum, hepatic hilus and retroperitoneum (max-
imal SUV approximately 8.39). Moreover, lesions with in-
creased density were found in the left third rib, the right
upper femur and the left acetabulum, which were accom-
panied by an increase in fluorodeoxyglucose. The patient
was diagnosed with PLC after liver transplantation due to
liver carcinoma.
The treatment with steroid and aminophylline continued
to improve the status of the patient’s interstitial lesions. Al-
though antirejection therapy was stopped, rejection did not
occur and the function of the graft liver was stable. Oral
capecitabine was administered but was not effective. The
patient experienced increasing chest tightness and short-
ness of breath, and he died as a result of respiratory failure
1 month later.
Discussion
PLC was first described by Troisier in 1873. About 30%
to 40% of malignancies may present with metastasis to
the lung, and PLC accounts for approximately 6% to 8%
of metastatic cancer in the lung. Most PLCs originate
from adenocarcinomas, and they are most often due to
lung cancer, followed by breast cancer and gastric can-
cer [2,3]. Patients with renal cancer, cervical cancer, thy-
roid cancer and melanoma rarely develop PLC [4-6].
The pathologic features of PLC include infiltration of
cancer cells and interstitial edema in and around
lymphatic vessels as well as infiltration of inflammatory
cells caused by lymph node metastasis in the lung. The
metastatic cancer in the mediastinal and pulmonary
hilar lymph nodes may obstruct lymphatic drainage,
resulting in retrograde migration of cancer cells into ter-
minal lung tissues via lymphatic vessels or anterograde mi-
gration of cancer cells in the pleura into the pulmonary
hilar lymph nodes through intrapulmonary lymph vessels.
In addition, a cancer embolus may form in the terminalvessels of the lung due to hematogenous metastasis, which
can invade the surrounding lymphatic vessels. Thus, hilar
and mediastinal lymph node metastasis may be present or
Figure 2 Computed tomography scans of the lungs. (A) Soon after the appearance of the patient’s respiratory symptoms, a computed
tomography (CT) scan revealed septal thickening of the peribronchovascular interstitium, pleural effusion, segmental atelectasis in the right lower
lobe of the lung and several enlarged lymph nodes in the mediastinum. (B) Discontinuation of anti-infection therapy, and 5 days after
thoracentesis, extensive involvement of the parenchyma with septal thickening was evident, with reticulonodular densities in all lung fields.
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primary cancer.
Extrahepatic metastasis of liver carcinoma is mostly
found in the lung, adrenal gland, bone and central nervous
system. Hematogenous spread is thought to be the most
common extrahepatic metastatic route [7,8]. In the liver,
lymphatic vessels run parallel to the interlobular vessels
and bile duct. Lymphatic vessels can be classified as deep
or superficial lymphatic collecting ducts. Superficial
lymphatic collecting ducts are often found in the connect-
ive tissues of the liver capsule, and the lymph is trans-
ferred into the parasternal, paracardial and abdominal
lymph nodes. The deep lymphatic collecting ducts con-
nect to one another to form upstream and downstreamFigure 3 Cancer cells among the exfoliated cells in the pleural
effusion are shown. All slides are stained with hematoxylin and
eosin and were photographed under light microscope at 400 ×
original magnification.trunks which transport lymph into the phrenic lymph
nodes around the terminal segment of the inferior vena
cava and hepatic and left gastric lymph nodes. Thus,
lymphatic metastasis of liver carcinoma may be found in
the hepatic hilar, upper abdominal and retroperitoneal
lymph nodes because of the parallel distribution between
lymphatic vessels and major abdominal blood vessels. In
addition, skip metastasis may be found in several groups
of lymph nodes. Overall, PLC is rare in liver carcinoma.
To date, to the best of our knowledge, PLC has not been
identified in patients who have undergone liver transplant-
ation due to liver carcinoma.
PLC patients usually develop progressive dyspnea,
cough, weight loss, fatigue and other symptoms, accom-
panied by hypoxemia, restrictive ventilatory dysfunction
and diffusion dysfunction [5]. The history of cancer or sur-
gery and characteristic features identified on lung CT scans
can be used to diagnose PLC after exclusion of interstitial
pneumonia, pulmonary fibrosis, sarcoidosis, pulmonary
embolism, heart failure and hematogenous disseminated
pulmonary tuberculosis. Biopsy and subsequent pathologic
examination are not required for the diagnosis of PLC [6,9].
In the early stages, lung CT shows interstitial lesions, linear
and reticular shadows and interlobar fissure thickening. Ap-
proximately one-third of PLC patients present with pleural
effusion (unilateral or bilateral). Once patients develop dys-
pnea, other findings may be present, including irregular
thickening of the tracheal vascular bundles and interlobular
septa, as well as multiple beaded, small nodules of varying
sizes (usually smaller than 3 mm in diameter) distributed
along the interlobular septa and pleura.
In our present case report, the patient was suspected
to have interstitial pneumonia due to Pneumocystis cari-
nii after transplantation. Thus, management was geared
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infection (SMZ and caspofungin); however, the response
to treatment was poor. On the basis of examination of
cancer cells in the pleural effusion and the PET-CT scan,
PLC was subsequently diagnosed. The positive rate of can-
cer cells in pleural effusion is 40% to 50%. This diagnos-
tic accuracy rate may increase if the sediment from the
pleural effusion is used for examination after being kept
for 24 hours. Although biopsy via bronchoscopy, pleuro-
centesis, lung puncture or thoracoscopy and subsequent
pathologic examination may confirm the diagnosis of
PLC, biopsy increases the risk of pneumothorax. Sputum
collection is relatively easy, but examination of exfoliated
cells in the sputum is associated with a low positive rate
[3]. Lung CT and PET-CT findings and cytology from the
pleural effusion can confirm the diagnosis of PLC. Al-
though a false-negative diagnosis of primary liver carcin-
oma is possible with the use of PET-CT (40% to 50%),
PET-CT has favorable sensitivity in the detection of extra-
hepatic metastasis of liver carcinoma. Acikgoz et al. [10]
reported that the detection rate of extrahepatic metastatic
foci ≥1 cm in diameter was as high as 92.9% in liver car-
cinoma patients after liver transplantation. There is evi-
dence that the specificity of PET-CT for PLC is 100% and
that the sensitivity is 86%. The mean SUV in the region of
PLC (1.37 ± 0.64) was significantly greater than that in the
normal lung (0.5 ± 0.29) (P < 0.0001) [11]. Thus, combined
examinations have an elevated detection rate compared to
a single examination. Examinations selected according to
the disease condition may significantly increase the detec-
tion rate.
To date, no effective strategies have been developed for
the treatment of PLC. Currently, antitumor therapy and
antispasmodic therapy of the airway with theophylline or
β2-adrenergic receptor agonists are used. However, these
treatments usually have poor efficacy, and PLC is associated
with a poor prognosis. Patients usually develop progressive
dyspnea and die as a result of respiratory failure and/or
heart failure. Approximately 50% to 85% of PLC pa-
tients have a survival time between 3 and 6 months
[12,13]. In our patient, PLC progressed rapidly because
of immunosuppression after liver transplantation. Although
immunosuppressive therapy was discontinued promptly,
the severity of the patient’s symptoms increased rapidly and
he died as a result of respiratory failure within 1 month.
In 1975, Kane et al. [14] reported the autopsy findings
from 7,524 patients with solid cancers that originated from
the prostate, breast, stomach, pancreas and liver. Involve-
ment of the pulmonary lymphatic system by cancer cells
was noted in 1,085 patients (only 1% of these patients died
as a result of respiratory failure). Although PLC is rarely
reported in liver carcinoma, the incidence of liver carcin-
oma–induced PLC might be far higher than previously re-
ported. In addition, liver carcinoma is highly malignant andprogresses rapidly. Although PLC may be present in liver
carcinoma patients, these patients might die as a result of
other causes, such as liver failure or hemorrhage due to
cancer rupture, before the typical symptoms of PLC mani-
fest. On the basis of our experience and previous reports,
clinicians should exclude PLC when patients develop hyp-
oxemia and interstitial pneumonia of unknown cause. PLC
may cause significant deterioration of the patient’s condi-
tion. Thus, only early identification, diagnosis and treat-
ment can prolong the survival of liver carcinoma patients
with PLC.
Conclusions
Although PLC is rare in liver carcinoma patients, cancer
cells can migrate into the pulmonary lymphatic system.
Early identification, diagnosis and treatment are crucial to
improving the survival of PLC patients. Combined use of
CT, PET-CT and pathologic examinations may significantly
increase the PLC detection rate. In our patient, immuno-
suppressive therapy after liver transplantation caused rapid
progression of PLC. Although we discontinued immuno-
suppressive therapy, employed strategies to improve the pa-
tient’s lung edema and administered antitumor therapy, the
efficacy of the treatment was still very poor.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
LT: Liver transplantation; PET-CT: Positron emission tomography/computed
tomography; PLC: Pulmonary lymphangitic carcinomatosis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Li Zhuang carried out clinical data collection, participated in the sequence
alignment and drafted the manuscript. XL and CH carried out pathological
analysis. Lin Zhang and GJ carried out clinical data collection, JW and SZ carried
out pathological analysis. All authors read and approved the final manuscript.
Acknowledgements
This work is supported by grants from the Zhejiang Medicines and Health
Technologies Program (201350072) and the National Natural Science
Foundation of China (NSFC 81000962).
Received: 1 July 2013 Accepted: 15 March 2014
Published: 27 March 2014
References
1. Grossman EJ, Millis JM: Liver transplantation for non-hepatocellular carcin-
oma malignancy: indications, limitations, and analysis of the current
literature. Liver Transpl 2010, 16:930–942.
2. Bruce DM, Heys SD, Eremin O: Lymphangitis carcinomatosa: a literature
review. J R Coll Surg Edinb 1996, 41:7–13.
3. Zhang K, Huang Y: [Clinical features and diagnosis of pulmonary
lymphangitic carcinomatosis [in Chinese]. Ai Zheng 2006, 25:1127–1130.
4. Otsubo K, Kubo N, Nakashima N, Izumi M, Nakamori M, Koto H: A juvenile
case of pulmonary lymphangitic carcinomatosis caused by sigmoid
Zhuang et al. World Journal of Surgical Oncology 2014, 12:66 Page 5 of 5
http://www.wjso.com/content/12/1/66colon cancer with a component of micropapillary carcinoma. Intern Med
2011, 50:2361–2365.
5. Wallach JB, McGarry T, Torres J: Lymphangitic metastasis of recurrent
renal cell carcinoma to the contralateral lung causing lymphangitic
carcinomatosis and respiratory symptoms. Curr Oncol 2011, 18:e35–e37.
6. Babu S, Satheeshan B, Geetha M, Salih S: A rare presentation of pulmonary
lymphangitic carcinomatosis in cancer of lip: case report. World J Surg
Oncol 2011, 9:77.
7. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL:
Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000,
216:698–703.
8. Molina DK, Valente PT: Lymphangitic spread of hepatocellular carcinoma.
Arch Pathol Lab Med 2003, 127:e11–e13.
9. Shin NY, Hong YJ, Kim AH, Shim HS, Nam JE, Lee HJ, Kim MJ: Diffuse
interstitial infiltrative lung metastasis of malignant melanoma: a case
report. Korean J Radiol 2011, 12:252–255.
10. Acikgoz G, Kim SM, Houseni M, Cermik TF, Intenzo CM, Alavi A: Pulmonary
lymphangitic carcinomatosis (PLC): spectrum of FDG-PET findings.
Clin Nucl Med 2006, 31:673–678.
11. Prakash P, Kalra MK, Sharma A, Shepard JA, Digumarthy SR: FDG PET/CT in
assessment of pulmonary lymphangitic carcinomatosis. AJR Am J
Roentgenol 2010, 194:231–236.
12. Regueiro F, Roche P, Regueiro MV, Lozano R: The importance of histology
in the evaluation of pulmonary transplantation: carcinomatous
lymphangitis. Thorac Cardiovasc Surg 2005, 53:122–123.
13. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M: Dramatic
effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung
cancer and poor performance status. Lung Cancer 2003, 40:73–76.
14. Kane RD, Hawkins HK, Miller JA, Noce PS: Microscopic pulmonary tumor
emboli associated with dyspnea. Cancer 1975, 36:1473–1482.
doi:10.1186/1477-7819-12-66
Cite this article as: Zhuang et al.: Pulmonary lymphangitic carcinomatosis
in liver carcinoma: a rare case report and literature review. World Journal of
Surgical Oncology 2014 12:66.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
